Prakash Srinivasan, PhD , Associate Professor at the Bloomberg School of Public Health (Johns Hopkins University), focuses on Malaria , Parasitology , and Vaccine Development . His work primarily targets Plasmodium falciparum , investigating host-parasite interactions and erythrocyte invasion mechanisms. Education: PhD, Case Western Reserve University (2007) MS, St. Joseph's College (1998) Research explores: Molecular mechanisms of parasite entry/exit from host cells Vaccine design using receptor-ligand interactions Small molecule inhibitors for protein-protein blocking Recent publications highlight trends in mRNA vaccines , machine learning for parasite counting , and RON11's role in rhoptry biogenesis . Collaborations include institutions like the Johns Hopkins Malaria Research Institute and global partners.
Stirling Churchman, Ph.D., is Professor of Genetics at Harvard Medical School and leads the Churchman Lab within the Blavatnik Institute. Her work integrates experimental and computational approaches to dissect the multiple layers of gene regulation, spanning transcription, RNA processing, and translation in both nuclear and mitochondrial systems. Education: While specific degrees are not detailed in the provided text, Dr. Churchman’s extensive publication record and faculty position at Harvard Medical School indicate advanced graduate and postdoctoral training in molecular biology and genomics. Research Interests: Nascent RNA dynamics: Using NET-seq and nanopore direct RNA sequencing to capture transcription and co-transcriptional processing at single-nucleotide resolution. Mitochondrial gene expression: Investigating how mitochondrial transcription and translation are synchronized with nuclear programs to maintain respiratory chain homeostasis. Chromatin architecture & single-molecule genomics: Employing Fiber-seq to visualize RNA polymerases and chromatin structure along native DNA fibers up to 30 kb in length. Post-transcriptional splicing kinetics: Quantifying intron removal dynamics in living cells to understand fidelity and timing of mRNA maturation. Across more than 60 publications (2011-2025), a clear trend emerges: Dr. Churchman develops cutting-edge sequencing technologies and applies them to fundamental questions in gene expression. Recent work (2024-2025) highlights a shift toward mitochondrial biology, antibiotic action on mitoribosomes, and the global quantification of RNA flow across cellular compartments. Scientific Awards & Honors: Specific named awards are not listed in the provided text; however, her continuous funding, high-impact publications, and professorial appointment at Harvard Medical School reflect significant peer recognition. Laboratory & Team: The Churchman Lab is located in the New Research Building at Harvard Medical School (Blavatnik Institute, Room 356). The team is interdisciplinary, combining expertise in biology, physics, chemistry, and computation to pursue integrative studies of gene regulation. Funding & Grants: While explicit grant numbers are not provided, the sustained productivity, large team, and resource-intensive technologies (e.g., nanopore sequencing, cryo-EM collaborations) indicate substantial and ongoing extramural funding from NIH and other agencies.
Noortje van den Dungen is a Researcher affiliated with the University Medical Center Utrecht under the Strategic Program Cancer . Her work bridges cardiovascular disease and cancer research, focusing on molecular mechanisms in atherosclerosis and immune regulation. Expertise : Single-cell transcriptomics, RNA methylation, vascular pathology Techniques : Machine learning for plaque imaging, molecular biomarker discovery Recent publications highlight her contributions to understanding endothelial-mesenchymal transitions , intraplaque hemorrhage quantification , and RNA methylation in CD4+ T cells . Collaborative projects span neurovascular disease and immunotherapy. Key collaborations involve institutions like UMC Utrecht, with co-authors exploring cancer-immunity intersections and high-risk vascular pathologies.
Michael Fried, Ph.D. , is a Professor in Molecular and Cellular Biochemistry , with affiliations to the Center for Structural Biology , Markey Cancer Center , and the Molecular and Cellular Oncology Research Program . His career spans decades, including roles at institutions like the Van Andel Institute (PI, 2022–2023) and collaborations with the University of North Carolina Chapel Hill (CoI, 2012–2014). Education: Doctor of Philosophy (1982) from Yale University , and Bachelor of Arts (1976) from Dartmouth College . Research Interests: Fried focuses on DNA repair , mutagenesis , and chemotherapy , with additional work on RNA splicing , PARP1 , and transmembrane domain interactions in viruses like SARS-CoV and Hendra virus. His studies employ techniques such as analytical ultracentrifugation , electrophoretic mobility shift assays , and structural biology . Recent Publications: His 2024 Scientific Reports article explores cooperative nucleic acid binding by PARP1, while 2018 works on nonribosomal peptides and viral fusion proteins highlight his interdisciplinary approach. Earlier studies (2015–2018) examine AGT cooperativity, DNA repair in telomeres, and paramyxovirus fusion domains. Grants: Active grants include roles as PI for the Van Andel Institute (2022–2023) and CoI on NSF-funded projects (2020–2022) studying RNA splicing and PARP1. Past collaborations (2012–2014) focused on viral proteins and DNA repair.
Albert Bowers is an Associate Professor in the Division of Chemical Biology and Medicinal Chemistry at the UNC School of Medicine , with affiliations in the Center for Integrative Chemical Biology and Drug Discovery , Department of Chemistry , and Lineberger Comprehensive Cancer Center . His research focuses on translating natural product insights into next-generation peptide macrocycle therapeutics. Research Interests : Synthesis and modification of natural product-derived therapeutic leads Integration of chemical synthesis, biosynthesis, and computational chemistry mRNA display for high-throughput peptide library screening Biocatalysis using RiPP enzymes for drug-like macrocycles Scientific Awards : Beckman Young Investigator Award (2014) AACP New Investigator Award (2013) NIH NCI Ruth L. Kirschstein Fellowship (2008-2011) NSF/JSPS Fellowship for Kyoto University (2005) Publications highlight advancements in mRNA display libraries, biocatalytic macrocyclization, and targeting protein-protein interfaces through structural and computational approaches.
Dr. Terrence (Terry) Furey is a Professor in the Department of Genetics and Biology at the UNC School of Medicine. His research focuses on gene regulatory processes, particularly epigenetically controlled mechanisms, and their role in complex diseases like inflammatory bowel diseases (IBD). The Furey Lab specializes in computational analysis of genome-wide open chromatin, histone modifications, miRNA, and gene transcription data from high-throughput sequencing experiments. Key research areas: Epigenetics, Chromatin Biology, IBD Pathogenesis, Computational Genomics, Microbiome Interactions Specialized methodologies: Development of statistical and computational tools for genomic data analysis Research highlights include investigating genetic and epigenetic contributors to IBD through collaborations with Dr. Shehzad Sheikh, particularly analyzing chromatin reprogramming, miRNA expression, and microbial composition in both IL-10 knockout models and human intestinal tissues. The lab has identified distinct molecular signatures of Crohn's disease associated with clinical phenotypes. Article trends demonstrate expertise spanning Chromatin accessibility analysis in disease states MicroRNA biomarker discovery in IBD Computational tool development (ROCCO, DeFCoM, GSAASeqSP) Multi-omics integration in complex phenotypes Environmental-genetic interaction studies Translational IBD research Dr. Furey actively collaborates with researchers across the Center for Gastrointestinal Biology and Disease (CGIBD), including Drs. Sartor, Sheikh, and Rusyn. His work bridges clinical/translational research with microbiome studies , focusing on how epigenetic landscape alterations contribute to disease progression.
Louie Van de Lagemaat is a bioinformatician at the University of Aberdeen's Centre for Genome-Enabled Biology and Medicine (School of Medicine, Medical Sciences and Nutrition), joining in October 2021. He holds a PhD in Genetics from the University of British Columbia (2006) and has extensive experience in genomic data analysis. Research Interests : Haematopoiesis, molecular neuroscience, and transcriptomics using high-throughput sequencing technologies. Expertise : ChIP-seq, RNA-seq, Ribo-seq, and meRIP-seq analysis, with a focus on HLA allele heterozygosity and epigenetic regulation. Collaborations : Active in interdisciplinary studies with researchers in stem cell biology, cancer genomics, and neurogenetics.
Dr. Mamta Amrute is an Associate Professor and Principal Investigator at the Institute of Molecular and Cell Physiology, Hannover Medical School (MHH), where she has led her research group since 2017. Her academic journey includes a PhD from MHH (2003-2006), postdoctoral research at MHH (2012-2016), and at the prestigious Medical Research Council-Laboratory of Molecular Biology in Cambridge, UK (2008-2011). Her research program focuses on single-molecule biophysics of molecular motor proteins , with particular emphasis on understanding how mutations in cardiac myosin lead to hypertrophic cardiomyopathy (HCM), a condition affecting approximately 1 in 200 individuals worldwide. The lab employs advanced techniques including Total Internal Reflection Fluorescence Microscopy, optical trapping, and zero-mode waveguides to investigate fundamental motor protein mechanisms. Analysis of recent publications reveals three major research trajectories: 1) Detailed characterization of cardiac and skeletal myosin isoforms at the single-molecule level, 2) Investigation of epigenetic regulation in muscle physiology and atrophy, and 3) Development of computational tools for biochemical research. This work has significant implications for understanding and potentially treating heart disease and muscle wasting conditions. Dr. Amrute's research is supported by multiple funding sources including the Deutsche Forschungsgemeinschaft (DFG), Fritz Thyssen Foundation, and MHH's early career research grant program (HilF). She supervises a diverse team of doctoral students and postdoctoral researchers, providing training in advanced biophysical techniques. The Amrute-Nayak Research Group maintains an extensive international collaboration network spanning institutions in the UK, USA, Japan, Italy, Sweden, and Australia, facilitating cross-disciplinary approaches to studying molecular motors and muscle diseases. Her work bridges fundamental biophysics with clinical applications in cardiology and muscle physiology.
Dr. Joachim Meißner is a researcher at the Institute of Molecular and Cell Physiology at Hannover Medical School (MHH). He leads research in the Konze Research Group, focusing on muscle physiology with particular emphasis on cardiac and skeletal muscle differentiation and function. His work spans from fundamental molecular mechanisms to applications in cardiac disease modeling. Dr. Meißner's research interests center on myosin expression patterns , stem cell-derived cardiomyocyte maturation , and the molecular mechanisms underlying muscle fiber type transformation . His laboratory investigates how mechanical forces, signaling pathways, and metabolic conditions influence muscle cell differentiation and function, with recent work focusing on human stem cell models of cardiac disease. Analysis of his recent publications shows a strong trend toward using advanced stem cell technologies to model cardiac diseases, particularly Hypertrophic Cardiomyopathy. His work combines single-cell analysis with functional measurements to understand how genetic variations affect contractile function at the cellular level. The research bridges fundamental molecular biology with potential clinical applications in cardiac tissue engineering. Dr. Meißner has maintained a consistent publication record spanning several decades, with recent work (2023-2025) showing continued productivity and relevance in the field of cardiac muscle research. His collaborations include multiple institutions and researchers working in stem cell biology, cardiology, and muscle physiology. His advising approach appears to focus on training students in advanced cell culture techniques, molecular biology methods, and functional analysis of muscle cells. Students working with him typically engage in projects related to stem cell differentiation, contractile function analysis, and molecular mechanisms of muscle disease. The research group utilizes primary muscle cell cultures, stem cell-derived cardiomyocytes, and advanced molecular techniques to investigate fundamental questions in muscle physiology. Current work emphasizes the maturation of stem cell-derived cardiomyocytes to ventricular-like phenotypes, which has significant implications for cardiac tissue engineering and disease modeling.
Kyle Mansfield, Ph.D., serves as Associate Professor in the Department of Biochemistry and Molecular Biology at the Brody School of Medicine, East Carolina University. His research program bridges molecular biology, cancer research, and cellular response to environmental stressors. Dr. Mansfield's research focuses on N6-methyladenosine (m6A) mRNA modification and its role in breast cancer progression and hypoxic response. His lab investigates how m6A levels change during cancer development, how RNA methyltransferases like METTL16 function, and how cells stabilize specific mRNAs during low oxygen conditions. This work has significant implications for understanding cancer biology and developing novel therapeutic approaches. Analysis of recent publications reveals a clear research trajectory from foundational work on cellular oxygen sensing toward current focus on RNA epigenetics in disease. The lab's publications demonstrate expertise in molecular techniques for studying RNA modification, protein-RNA interactions, and cancer cell phenotypes. Dr. Mansfield's research is supported by competitive funding including an American Cancer Society Research Scholar Grant and Brody Brothers Endowment Award, reflecting the significance and innovation of his work in RNA biology and cancer research. The lab maintains active collaborations within East Carolina University, particularly with cancer biology and vascular research groups, creating an interdisciplinary environment for investigating RNA modification in disease processes.
Baoguo Ren, MD, serves as a Research Instructor at the University of Pittsburgh, leading department-wide and university-wide initiatives in high-throughput sequencing for precision medicine applications. His work bridges molecular diagnostics and cancer therapeutics within the medical research ecosystem. Dr. Ren's educational foundation includes: M.D. from West China University of Medical Sciences His research program centers on RNA-Seq, Exome-Seq, and Single Cell-Seq technologies to decode cancer biology and develop molecular interventions. This work integrates genomic analysis with therapeutic innovation, particularly in antibody-based treatments and mRNA modification strategies for precision oncology. The research demonstrates strong translational potential for improving cancer diagnostics and targeted therapies. Publication analysis from 2006-2017 reveals consistent contributions to cancer genomics, with increasing emphasis on sequencing technologies. Early work focused on mutation analysis in prostate/liver cancers (2006-2008), evolving toward RNA biology and molecular diagnostics applications (2010-2017), reflecting the field's technological advancement and clinical integration. Dr. Ren coordinates high-throughput sequencing infrastructure across the University of Pittsburgh, facilitating collaborative research in genomics and molecular medicine. His position enables cross-departmental engagement in advancing precision medicine initiatives through shared technical resources and expertise.
Dr. Kelly Oh is a Research Assistant Professor in the Department of Cell Biology and Anatomy at the Chicago Medical School, Rosalind Franklin University, where she has conducted research since 2008. Her work focuses on Duchenne Muscular Dystrophy (DMD) pathogenesis using C. elegans as a model system to investigate muscle cell death mechanisms and regenerative responses. Her educational background includes a PhD in Cellular and Molecular Biology from Roswell Park Cancer Institute, SUNY at Buffalo (1999), followed by a postdoctoral fellowship at UCSF (1999-2007) and industry experience at Applied Biomics (2007-2008). PhD: Cellular and Molecular Biology, Roswell Park Cancer Institute, SUNY Buffalo (1999) Postdoc: University of California, San Francisco (1999-2007) Industry: Applied Biomics, Senior Scientist (2007-2008) Dr. Oh's research program centers on understanding how dystrophin deficiency causes progressive muscle degeneration and identifying therapeutic targets through signaling pathway modulation. Her laboratory has demonstrated that IGF-1 signaling and stress response pathways play critical roles in preventing muscle cell death in dystrophic models. This work bridges fundamental cell biology with translational applications for muscular dystrophy treatment, utilizing genetic, molecular, and physiological approaches in C. elegans to uncover conserved mechanisms relevant to human disease. Analysis of her publication record reveals consistent focus on muscular dystrophy mechanisms over 15+ years, with increasing emphasis on IGF-1 signaling and dystrophin complex function after 2009. Her work spans molecular genetics, cell physiology, and signal transduction, with strong translational potential for identifying therapeutic targets in muscle degenerative diseases. The majority of publications utilize C. elegans models to dissect conserved pathways, demonstrating methodological consistency while expanding into BK channel regulation and sex determination mechanisms in earlier career stages. Dr. Oh maintains active research collaborations across multiple institutions, as evidenced by co-authorships with researchers from UCSF, international universities, and medical research centers. Her laboratory operates within Rosalind Franklin University's infrastructure supporting molecular and cellular research in muscle biology, though specific grant details are not publicly enumerated.
Professor Joel Mackay is a physical biochemist at the University of Sydney, where he holds the Chair of the Biochemistry, Molecular and Cell Biology cluster in the School of Life and Environmental Sciences and serves as President of the Australian Society for Biochemistry and Molecular Biology. Since arriving in 1995 he has built an internationally recognised laboratory focused on protein structure–function, gene regulation and designer peptide engineering, supported by ~$30 M of competitive funding. Education: PhD — University of Cambridge, UK (1994) Research interests: The Mackay group deciphers how proteins work at the molecular level, concentrating on two synergistic themes: Molecular mechanisms that govern eukaryotic gene expression, with emphasis on transcription factors, chromatin remodelers (CHD4/NuRD), epigenetic modifications and zinc-finger domains. Exploitation of cutting-edge library-display technologies to create bespoke peptides and mini-proteins that modulate challenging therapeutic targets such as BET bromodomains. Methodologically the lab integrates molecular biology, cell biology, biophysics and structural techniques (NMR, X-ray crystallography, SPR, AUC, MST, XL-MS) and has access to 600 & 800 MHz NMR, crystallisation, fermentation and proteomics facilities. Major discoveries: First demonstration that zinc-finger domains can act as protein–protein interaction modules, overturning the dogma that they bind only nucleic acids. Elucidation of how acetylation of the transcription factor GATA1 recruits the epigenetic reader BRD3, providing early mechanistic insight into post-translational control of transcription factors. Structural and functional characterisation of AHSP, the long-sought chaperone for α-globin, illuminating molecular bases of β-thalassemia and sickle-cell disease. Scientific honours: Biophysics Young Investigator Award 1997 Roche Molecular Biochemicals Medal 2001 Science Minister’s Prize for Life Sciences (under 35) 2002 ANZMAG Young Investigator Medal 2002 Gottschalk Medal (AAS) 2006 Labgear Discovery Science Award 2016 ARC & NHMRC Research Fellowships (1995-2019) Leadership & grants: Prof. Mackay has secured continuous national (ARC DP, Linkage, ITTC; NHMRC Project & Program) and international (NIH R01) funding totalling ~$30 M. He currently leads a 40-member academic cluster and mentors five doctoral researchers working on epigenetic inheritance, hemoglobinopathies, pollinator protection and chromatin dynamics. Collaborations & infrastructure: Active partnerships with groups in Germany, New Zealand, the USA and the UK leverage the University of Sydney’s flagship institutes—Sydney Institute of Agriculture, Centre for Drug Discovery Innovation and Sydney Nano—to translate fundamental protein discoveries into agricultural, medical and biotechnological applications.
Emil Ylikallio is an Associated Clinical Researcher at the Medical Neurogenetics Lab within the Stem Cells and Metabolism Research Program (STEMM) at the University of Helsinki. He concurrently serves as a Clinical Neurologist and heads the Rare Neurological Diseases Program at HUS Helsinki University Hospital. His academic appointments include positions in the Department of Neurosciences and Center of Excellence in Stem Cell Metabolism, where he supervises doctoral candidates in Clinical Research and Biomedicine. Education includes: Licentiate of Medicine (Mechanisms and Effects of Mitochondrial DNA Instability) - University of Helsinki, Faculty of Medicine (2011) Master of Medical Sciences - University of Helsinki, Faculty of Medicine (2010) Research focuses on molecular mechanisms of neurodegenerative conditions, with particular expertise in: Motor neuron disease pathogenesis and metabolic alterations Hereditary peripheral neuropathies including Charcot-Marie-Tooth variants Mitochondrial dysfunction in neurological disorders Stem cell models of neuromuscular diseases His work bridges clinical neurology with basic research in neurogenetics. Publication analysis reveals strong focus on: Genetic basis of peripheral neuropathies and motor neuron disorders Metabolic dysregulation in neuromuscular conditions Stem cell modeling of neurological diseases Identification of novel biomarkers and therapeutic targets Research employs cutting-edge techniques including cellular reprogramming, CRISPR modification, and multi-omics approaches. Current research leadership includes: Principal Investigator for 'Axon degeneration: new mechanisms, biomarkers and treatment' project (Funded by Academy of Finland) Project lead for Swedish Masonic Order-funded research (2025-2027) Supervises doctoral candidates and serves on national/international committees. Leads research activities through the Medical Neurogenetics Lab and collaborates extensively with HUS Neurocenter. Team focuses on translational research bridging molecular discoveries with clinical neurology applications.
Matjaz Barboric is a University Researcher in the Department of Biochemistry and Developmental Biology at the University of Helsinki, where he serves as a Supervisor in the Doctoral Programme in Biomedicine. His research is supported by multiple active projects funded by the Academy of Finland, Cancer Foundation, Sigrid Jusélius Foundation, and Magnus Ehrnrooths Foundation, with research extending through 2028. Dr. Barboric's research program focuses on the fundamental mechanisms of metazoan gene transcription by RNA polymerase II, particularly investigating regulatory factors that modulate transcription at the elongation level. His laboratory studies key cyclin-dependent kinases that stimulate RNAPII elongation and phosphorylate the C-terminal domain of Rbp1 at Serine 2. Using biochemical, genetic, and systems biology approaches, his team explores how transcription elongation connects to pre-mRNA processing events like alternative splicing through Ser2-P CTD modification. A critical aspect of his work examines how deregulation of RNAPII elongation control contributes to cancer development and investigates the significance of transcription elongation kinases in embryonic development. Analysis of Dr. Barboric's publication record spanning over two decades reveals consistent focus on transcriptional regulation mechanisms, with recent work increasingly connecting fundamental transcription processes to cancer biology. His research demonstrates strong interdisciplinary connections between basic molecular mechanisms and clinical applications, particularly in identifying how transcriptional dysregulation contributes to disease states and potential therapeutic targets. Dr. Barboric currently leads multiple research projects including 'Combinatorial targeting of transcriptional kinases in cancer' funded by the Academy of Finland (2024-2028), multiple Cancer Foundation projects (2024-2026), and the M&GC. Ehrnrooth Foundation project (2025). He serves as a supervisor for doctoral students in the Biomedicine program, with documented supervision of research on 'Regulation of Pol II polymerase transcriptional response to DNA damage by RBM7 and P-TEFb' in 2020.
